ModeX Therapeutics, Regeneron Collaborate on Multispecific Antibodies with $7M Upfront

ModeX Therapeutics, a subsidiary of OPKO Health, has entered a license and collaboration agreement with Regeneron Pharmaceuticals to develop multispecific antibodies targeting multiple pathways for diseases including immunology, oncology, and metabolic disorders, with the partnership potentially exceeding $1 billion in value. ModeX utilizes its MSTAR platform to create innovative antibody candidates, some of which are already in clinical trials. The company has initiated a Phase 1/2a clinical trial for MDX2004, a trispecific antibody-fusion protein designed to activate T cells via CD3, CD28, and 4-1BB receptors, aiming to enhance immune responses against advanced cancers. MDX2004 seeks to rejuvenate and expand T cell populations to improve outcomes for patients with limited treatment options and low long-term survival rates. Preclinical and clinical data supporting MDX2004 will be presented at the Society for Immunotherapy of Cancer Annual Meeting. ModeX's collaboration with Regeneron includes upfront payments and potential milestone and royalty revenues, while Regeneron will handle further development and commercialization of selected products.